Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41068 | 0.82 | — | — | |
| SCHEMBL27575513 | 0.81 | CYP1A2 (0.41) | GAASMN1; SMN2MAPTLMNARAB9A | |
| SCHEMBL27640916 | 0.81 | RAB9A (0.46) | GAASMN1; SMN2MAPTL3MBTL1LMNA | |
| Hydrochloric Acid SCHEMBL272523 | 0.79 | — | — | |
| SCHEMBL28851694 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL23174893 | 0.79 | — | — | |
| SCHEMBL27503883 | 0.79 | — | — | |
| SCHEMBL3882468 | 0.79 | FFAR3 (0.43) | FFAR1LMNATSHRALDH1A1EGLN1 | |
| Ammonia Solution, Strong SCHEMBL1361604 | 0.79 | — | — | |
| SCHEMBL31198194 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357435-A1 | USE OF INHIBITORS OF ADAM12 AS ADJUVANTS IN TUMOR THERAPIES | PASTEUR INSTITUT (FR) | 2023-11-09 | — | — | US | disclosed |
| US-11780934-B2 | Use of inhibitors of ADAM12 as adjuvants in tumor therapies | INSTITUT PASTEUR (FR) | 2023-10-10 | — | — | US | disclosed |
| EP-3358351-B1 | ADAM12 INHIBITORS AND THEIR USE AGAINST INFLAMMATION-INDUCED FIBROSIS | PASTEUR INSTITUT (FR) | 2021-06-16 | — | — | EP | disclosed |
| US-10961536-B2 | ADAM12 inhibitors and their use against inflammation-induced fibrosis | INSTITUT PASTEUR (FR) | 2021-03-30 | — | — | US | disclosed |
| US-20200261577-A1 | METHODS OF PREVENTING SECONDARY INFECTIONS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-08-20 | — | — | US | disclosed |
| US-10610588-B2 | Methods of preventing secondary infections | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-04-07 | — | — | US | disclosed |
| US-20190031776-A1 | USE OF INHIBITORS OF ADAM12 AS ADJUVANTS IN TUMOR THERAPIES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2019-01-31 | — | — | US | disclosed |
| EP-3410849-A1 | USE OF INHIBITORS OF ADAM12 AS ADJUVANTS IN TUMOR THERAPIES | Institut Pasteur (FR) | 2018-12-12 | — | — | EP | disclosed |
| EP-3358351-A1 | ADAM12 INHIBITORS AND THEIR USE AGAINST INFLAMMATION-INDUCED FIBROSIS | Institut Pasteur (FR) | 2018-08-08 | — | — | EP | disclosed |
| US-20180134808-A1 | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-05-17 | — | — | US | disclosed |
| US-5932577-A | OSTEOPOROSIS; ANTIARTHRITIC AGENTS; ANTIINFLAMMATORY AGENTS;NERVOUS SYSTEM DISORDERS; ANTITUMOR AGENTS; CARDIOVASCULAR DISORDERSANTITUMOR AGENTSD | BAYER CORPORATION (US) | 1999-08-03 | — | — | US | disclosed |
| US-5925637-A | ENZYME INHIBITORS AS ANTIARTHRITIC AGENTS OR CARDIOVASCULAR DISORDERS | BAYER CORPORATION (US) | 1999-07-20 | — | — | US | disclosed |
| EP-0912487-A1 | SUBSTITUTED OXOBUTYRIC ACIDS AS MATRIX METALLOPROTEASE INHIBITORS | Bayer Corporation (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0912496-A1 | INHIBITION OF MATRIX METALLOPROTEASES BY ACETYLENE CONTAINING COMPOUNDS | Bayer Corporation (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0904260-A1 | INHIBITION OF MATRIX METALLOPROTEASES BY 2-(OMEGA-AROYLALKYL)-4-BIARYL-OXOBUTYRIC ACIDS | Bayer Corporation (US) | 1999-03-31 | — | — | EP | disclosed |
| US-5804581-A | ADMINISTERING ENZYME INHIBITOR TO TREAT OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, SEPTIC ARTHRITIS, PERIODONTAL DISORDERS, CORNEAL ULCERATION, PROTEINURIA, OSTEOPENIAS, DYSTROPHY, CORONARY THROMBOSIS, TUMOR METASTASIS AND BULLOSA | BAYER CORPORATION (US) | 1998-09-08 | — | — | US | disclosed |
| WO-1997043238-A9 | SUBSTITUTED OXOBUTYRIC ACIDS AS MATRIX METALLOPROTEASE INHIBITORS | — | 1998-03-05 | — | — | WO | disclosed |
| WO-1997043238-A1 | SUBSTITUTED OXOBUTYRIC ACIDS AS MATRIX METALLOPROTEASE INHIBITORS | BAYER CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| WO-1997043245-A1 | INHIBITION OF MATRIX METALLOPROTEASES BY ACETYLENE CONTAINING COMPOUNDS | BAYER CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| WO-1997043240-A1 | INHIBITION OF MATRIX METALLOPROTEASES BY 2-(φ-AROYLALKYL)-4-BIARYL-OXOBUTYRIC ACIDS | BAYER CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134808-A1 | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS | VSIG8, ADAM8, IGSF11 | MMP12 7/4885GAA 257/4885MMP1 46/4885 |
| US-10961536-B2 | ADAM12 inhibitors and their use against inflammation-induced fibrosis | ADAM12, ADAM17, MMP12 | MMP12 3/4885GAA 1336/4885MMP1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.